Description: The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death.
The majority of hypertensive patients have primary (or essential) hypertension, that is, hypertension in which secondary causes are not present. Management aims to control arterial pressure, prevent end-organ damage (cerebrovascular, cardiovascular, and renal), and reduce the risk of premature death.
Antihypertensive drugs may be divided into two broad groups, the first group being those which directly or indirectly block the renin–angiotensin system (RAS), for example, ACEIs, angiotensin receptor antagonists (ARAs), direct renin inhibitors (DRIs), and to a lesser extent β-blockers. The second group of drugs works by increasing water and sodium excretion, thereby reducing intravascular volume, or by causing vasodilatation through non-RAS pathways, for example, diuretics and calcium channel blockers (CCBs).
MCE offers a unique collection of 481 compounds with identified and potential antihypertensive activity. MCE Antihypertensive Compound Library is critical for antihypertensive drug discovery and development.
MCE Antihypertensive Compound Library can be supplied as pre-dissolved Solutions or Solid. For pre-dissolved solutions in this library, there are 472 compounds supplied in 10 mM solution and 9 compounds supplied in 2 mM solution.
For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, and 2 mM for compounds with solubility between 2 mM and 10 mM.
Advantages:
- A unique collection of 481 antihypertensive inhibitors for high throughput screening (HTS) and high content screening (HCS).
- A useful tool for the study of critical for drug discovery and development.
- Target diverse, medicinally active and cell permeable.
- Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.
- More detailed compound information with structure, IC50, and other chemical & biological data.
- High purity and quality validated by NMR and LC/MS.
Formulation: A collection of 481 antihypertensive inhibitors supplied as pre-dissolved Solutions or SolidSolution:472 compounds supplied in 10 mM solution,9 compounds supplied in 2 mM solution.
Layout: 96-well storage tube or 96-well plate: 1st and 12th column are left empty.384-well plate: the first two columns and the last two columns are left empty.Compounds with different concentrations or dissolved in different solvents will be put on separate plates.This way of layout may increase the number of plates because there could be three solvents and three concentrations. If you have other requirements, please let us know.
Container: 96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode
English
Deutsch
